News & Updates

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab leads to acceptable survival outcomes and a reduction in severe dermatological toxicities in patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC), according to the results of a single-arm phase II HYBRID trial.

Atopic dermatitis (AD) does not seem to induce an increase in the risk of venous thromboembolism (VTE) when considering underlying risk factors, suggests a study. Moreover, patients with AD show a lower VTE risk than those with rheumatoid arthritis (RA), Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), or ankylosing spondylitis (AS).

Analysing molecular signatures from active skin lesions aids in the stratification of patients with contact dermatitis (CD) and helps identify those with allergic CD, suggests a study.

Low-dose oral minoxidil demonstrates comparable efficacy to 5% topical minoxidil in the treatment of androgenetic alopecia in men, offering a viable option for those who prefer oral therapy or those who poorly tolerate topical treatment, as shown in a study.

Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.